Study Sponsored by Optigenex Inc. and conducted by the University of Northern Arizona led by Doctor Oneil Guthrie, demonstrates significant statistical improvements, "p value less than .05," in key neurogenic markers including Focus and Attention, plus improvements in Memory and Executive Function

HOBOKEN, NJ / ACCESS Newswire / September 16, 2025 / Optigenex announced today results from daily oral intake of ac-11®. The data demonstrates statistically significant improvement in attention, memory and executive function. Additionally, 64 percent of the participants evidenced improvement in social cognition. Social cognition refers to a complex set of mental abilities underlying social stimulus perception, processing, interpretation and response. Improvement in attention and focus was the most resilient and persistent benefit. Conclusion: Healthy individuals with normal cognition may use ac-11® to provide a "Cognitive Boost."

Study Design:

The study deployed a randomized double-blind placebo cross-over design. Randomized, double-blind placebo-controlled trials involve the placement of participants into two groups. The first group started the study by taking a neuropsychological assessment at baseline. The base-line assessment was administered to determine the participants normal cognitive function. After normal neuro-function was determined, the participants consumed ac-11 daily for one month. AC-11® intake included oral consumption of one 350 mgs capsule twice per day (total of 700 mgs/day) for 30 days. At the end of the 30-day period, participants took the neuropsychological assessments again to determine whether ac-11® induced an improvement in scores from the baseline. Following our study design, these same participants did not consume ac-11 for 30 days. Specifically, they did not take ac-11 or a placebo. At the end of this washout period, the same participants took the assessment again. They then consumed the placebo (350 mg capsule twice daily, total 700 mgs per day) for 1 month. At the end of the 30-day period they took the assessment for the final time.

The second group followed generally the same protocol starting with the baseline assessment. The second group protocol differed from the first as they began with a 30-day period with placebo intake (700mgs/day) followed by another assessment, then a 30-day washout period, another assessment and finally a 30-day period of 700mgs/day of ac-11 followed by a final assessment.

Combining the two cross-over designs provides a rigorous, confirmative and powerful experimental approach for determining and evaluating efficacy of ac-11 in cognitive improvements. It should be noted, each researcher and participant were "blinded," to the scoring of each neuropsychological assessment. Unblinding occurred after test scores and data tabulations. The aim of the study was to determine whether ac-11can improve cognitive function among individuals with normal cognitive function.

Results:

Four cognitive domains were assessed in the study. They included focus, memory, executive function and social cognition.

The results revealed that oral intake of ac-11 improved cognitive functions across demographic groups from males to females, young to old, educated to less educated, and across ethnic groups. These improvements were statistically significant over placebo intake. They were also statistically significant months after the initial ac-11 intake.

Doctor Oneil Guthrie Ph.D. and Chief Investigator commented:

"It has long been the case that individuals have pursued a variety of means to boost their cognitive performance before exams (college students), before sporting events, before occupational pursuits, and before recreational and social activities. Until now, there were no safe and natural means of achieving such cognitive boost. The current study emphasized statistical rigor and a superior experimental design to interrogate the efficacy of ac-11 in boosting cognition. The results are highly encouraging and pave the way for future research and development"

Daniel Zwiren, CEO of Optigenex added:

"To our knowledge, there is no other natural ingredient on the market today that possesses the therapeutic value of ac-11®. Cognitive enhancement represents another, among the many, important health claim associated with ac-11". Zwiren continued, "We are pleased to announce the grant of United States Patent Number: 11,883,457 "Method of Enhancing Cognition in Individuals with Healthy Brain Function." This award underscores the exclusivity and proprietary health benefits of our technology." Zwiren continued; "One may imagine the benefits if ac-11® was administered to a group of cognitively impaired individuals."

Optigenex is the owner. distributor and provider of proprietary next generation, dietary supplements, skincare products and bulk ingredient featuring ac-11® as its core technology. AC-11® (also known as CMED-100®) is a patented bioactive water-soluble ingredient derived from the medicinal plant Uncaria tomentosa. For more information about Optigenex, please visit our website: www.optigenex.com

The statements made in this press release have not been evaluated by the FDA. The technology mentioned herein are not intended to treat, diagnose, cure or prevent any disease.

CONTACT:
Daniel Zwiren, CEO
Tel.: 201 638 3810
Email: dzwiren@optigenex.com

SOURCE: Optigenex, Inc.